menu
    • menu

    Company profile for Sigma-Aldrich Corporation

    Mix Gif-PSE
    News
    Merck Signs Long-Term Renewable Energy Contract for Korea Sites

    04 Nov 2025

    // PRESS RELEASE

    Merck to Acquire Chromatography Business of JSR Life Sciences

    15 Oct 2025

    // PRESS RELEASE

    Merck Launches AAW™ Workstation

    15 Jul 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    BPI Europe

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Related CompaniesRelated Companies

    About

    Sigma-Aldrich, part of Merck KGaA, Darmstadt, Germany, offers over 300,000 high-quality lab materials, technologies, and services to support research and biotech production. Committed to simplifying processes and enhancing efficiency, it helps accelerate access to better health solutions. Through innovation and collaboration, Sigma-Aldrich empowers discoveries that transform healthcare and improve lives. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sigma-Aldrich CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3050 Spruce St, St. Louis, MO 63103
    Telephone
    Telephone
    +1800 5218956
    Client Email
    Email
    mahirs.patel@merckgroup.com
    Client Website
    Website
    https://www.sigmaaldrich.com/IN/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sigma-aldrich/
    youtube
    YouTube
    https://www.youtube.com/@milliporesigma2407
    Twitter
    Twitter
    https://x.com/MilliporeSigma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Reference Standards 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/sigma-aldrich-corporation-party-content-66594.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/sigma-aldrich-corporation-party-content-23716.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    The global pharmaceutical excipients market continued to evolve in the third quarter (Q3) of 2025, supported by rising demand for functional excipients, growth in production of generics, and advances in drug delivery technologies. The global market for pharmaceutical excipients was estimated at US$ 9.8 billion to US$ 10.7 billion in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 4.1 to 6.6 percent through 2030. At this pace, the market is expected to reach US$ 13.05 billion to US$ 14.86 billion by 2030. Europe retained the largest market share in 2024, followed by Asia-Pacific. Key drivers shaping the excipients market include the rising prevalence of chronic diseases, expansion of biologics and biosimilars, and increasing quality and regulatory expectations. Increased investments in facility expansions and ongoing reforms in clinical trial regulations are also facilitating market growth. The sector remains highly competitive and fragmented. Major excipient providers include BASF, Roquette, Gangwal Healthcare, DuPont, Evonik, Seqens, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Colorcon, Kewpie Corporation, ICE Pharma, Nanjing Well Pharmaceutical, Merck KGaA owned MilliporeSigma, Minakem, Ashland Global, Actylis and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)  Evonik in partnership with Ethris; Colorcon Ventures invests in Phytolon   The market saw strategic collaborations across the excipients and drug formulation ecosystem in Q3 2025. Evonik entered into a partnership with Ethris to strengthen its nucleic acid delivery platform. The collaboration integrates Ethris’ proprietary technology — its lipidoid nanoparticle platform, known as SNaP LNP — into Evonik’s CDMO offerings, enhancing the latter’s ability to support RNA-based therapeutics from concept to clinic. Colorcon Ventures, the investment arm of Colorcon, announced a strategic investment in Israel-based Phytolon. The biotechnology start-up uses precision fermentation to develop natural colorants. The investment underscores Colorcon’s commitment to next-generation coloring technologies that support cleaner-label formulations and innovation in oral solid dosage coatings.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Evonik launches MaxiPure Polysorbate 80; Asahi Kasei expands its portfolio The quarter saw continued innovation in high-purity and injectable-grade excipients. Evonik introduced MaxiPure Polysorbate 80, a high-purity injectable-grade surfactant designed for biologics and parenteral formulations. This excipient addresses key challenges such as protein stability, viral inactivation, and the solubilization of hydrophobic APIs, while meeting regulatory expectations across global markets. Asahi Kasei expanded its Sonanos portfolio of excipients with two new products — Sonanos PG (optimized for sustained release of biologics and peptides while supporting patient-friendly dosing)  and Sonanos DS (developed to enhance solubility of poorly water-soluble APIs). These additions reflect growing industry demand for dosage optimization, stability, and specialized delivery of complex molecules. Gangwal Healthcare operates EXCiPACT-certified GMP facilities and offers a broad range of functional excipients, including co-processed blends like ProBlend, Starlose, and Microlose. Its excipients, including Solvostar (sodium starch glycolate) and Sallyso (croscarmellose sodium), support enhanced tablet disintegration and drug release. The company also provides taste-masking agents such as SucreX (sucralose) and CutCal (neotame), supporting the development of patient-friendly oral dosage forms.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Colorcon, Gattefossé, Croda, Roquette, Clariant expand manufacturing capacities Manufacturing investments and facility expansions remained a key trend during Q3 2025. Colorcon inaugurated a new state-of-the-art, film coating manufacturing facility in Johor, Malaysia. The site incorporates energy-efficient systems and advanced production technologies to strengthen Colorcon’s functional-excipient supply network across Asia. Gattefossé opened a new lipid-based excipient facility in Texas (US), marking a strategic expansion of its North American manufacturing footprint. Croda International expanded its Leek, UK facility with a lipid system synthesis unit and enhanced R&D capabilities. The site will support the launch of Super Refined Poloxamer 188, a highly purified fast-dissolving granular excipient. Roquette announced the opening of a dedicated innovation center in São Paulo, Brazil, strengthening its engagement with regional drug developers. Clariant expanded its Daya Bay, China facility, adding a second spray tower dedicated to pharmaceutical excipient production. The upgraded site increases capacity for excipients used in laxatives and other formulations. BASF also strengthened its commitment to biopharma and pharmaceutical ingredients with a new GMP Solution Center in Michigan (US). The facility expands BASF’s network of poloxamer (a synthetic polymer) manufacturing sites. With state-of-the-art clean room packaging and high-sensitivity analytical testing, this new facility will enable close collaboration with BASF’s customers on customized chemistries for product development.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   India mandates excipient disclosure; new rules to apply from March 2026  India has made it mandatory to disclose excipient details from March 2026 under the country’s new Drugs (2nd Amendment) Rules, 2025. This applies to Schedule H2 medicines. The final notification expands earlier draft requirements by mandating qualitative excipient details in QR codes on product packaging. This should enhance transparency and support patient safety. Meanwhile, US pharmaceutical groups have responded to the US Food and Drug Administration’s draft guidance proposing simplified pathways for replacing color additives in drug products. Industry associations have supported draft guidance, noting that it reduces regulatory burden while maintaining product quality and consistency.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Our view While the fast-growing generics market is creating demand for cost-effective and versatile excipients, the market is also witnessing innovations tailored to the specialized needs of biologics and biosimilars. India is poised to become a key player in the global excipient market, supported by the rapid growth in its generic drug industry, expansion of its health infrastructure and increasing investments in R&D. The new excipient-disclosure rules, therefore, are likely to benefit the global excipient industry by improving transparency and strengthening quality ecosystems.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 6329

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-evonik-launches-high-purity-excipients-india-mandates-disclosures-from-march-2026

    #PharmaFlow by PHARMACOMPASS
    20 Nov 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck Signs Long-Term Renewable Energy Contract for Korea Sites
    Merck Signs Long-Term Renewable Energy Contract for Korea Sites

    04 Nov 2025

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/long-term-energy-renewal-contract-south-korea

    PRESS RELEASE
    04 Nov 2025
    Share Share
    Merck to Acquire Chromatography Business of JSR Life Sciences
    Merck to Acquire Chromatography Business of JSR Life Sciences

    15 Oct 2025

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/acquisition-jsr-life-sciences

    PRESS RELEASE
    15 Oct 2025
    Share Share
    Merck Launches AAW™ Workstation
    Merck Launches AAW™ Workstation

    15 Jul 2025

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/aaw-workstation-to-advance-lab-automation

    PRESS RELEASE
    15 Jul 2025
    Share Share
    MilliporeSigma, Simtra combine in ADC Manufacturing Partnership
    MilliporeSigma, Simtra combine in ADC Manufacturing Partnership

    12 Jun 2025

    // PRESS RELEASE

    https://simtra.com/wp-content/uploads/2025/10/Simtra-Strategic-Alliance-Press-Release.pdf

    PRESS RELEASE
    12 Jun 2025
    Share Share
    Merck Announces Emerging Biotech Grant Program Winners
    Merck Announces Emerging Biotech Grant Program Winners

    01 Nov 2024

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/emerging-biotech-grant-program-winners

    PRESS RELEASE
    01 Nov 2024
    Share Share
    Merck Invests €70M To Expand ADC Manufacturing For Cancer Care
    Merck Invests €70M To Expand ADC Manufacturing For Cancer Care

    29 Oct 2024

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/adc-manufacturing-for-novel-cancer-therapies

    PRESS RELEASE
    29 Oct 2024
    Share Share

    Excipients

    Discover the DDS // excipients from this company

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company
    Pop Up

    ABOUT THIS PAGE

    Contact Sigma-Aldrich Corporation and get a quotation

    Sigma-Aldrich Corporation is a supplier offers 25 products (APIs, Excipients or Intermediates).

    Find DL-Ornithine hydrochloride bulk with DMF offered by Sigma-Aldrich Corporation

    Find Elapegademase bulk with JDMF offered by Sigma-Aldrich Corporation

    Find Sodium Pyruvate bulk with DMF offered by Sigma-Aldrich Corporation

    Find Acepromazine bulk offered by Sigma-Aldrich Corporation

    Find Bicisate Dihydrochloride bulk offered by Sigma-Aldrich Corporation

    Find Brompheniramine Maleate bulk offered by Sigma-Aldrich Corporation

    Find Clomipramine Hydrochloride bulk offered by Sigma-Aldrich Corporation

    Find Copper TetraMIBI Tetrafluoroborate bulk offered by Sigma-Aldrich Corporation

    Find Dimethyl Fumarate bulk offered by Sigma-Aldrich Corporation

    Find Doxylamine Succinate bulk offered by Sigma-Aldrich Corporation

    Find DPPC bulk offered by Sigma-Aldrich Corporation

    Find Glatiramer Acetate bulk offered by Sigma-Aldrich Corporation

    Find Halofuginone bulk offered by Sigma-Aldrich Corporation

    Find Indocyanine Green bulk offered by Sigma-Aldrich Corporation

    Find Inosine bulk offered by Sigma-Aldrich Corporation

    Find Lactobacillus Acidophilus bulk offered by Sigma-Aldrich Corporation

    Find Mebrofenin bulk offered by Sigma-Aldrich Corporation

    Find Mechlorethamine bulk offered by Sigma-Aldrich Corporation

    Find Nortriptyline bulk offered by Sigma-Aldrich Corporation

    Find Paricalcitol bulk offered by Sigma-Aldrich Corporation

    Find Promethazine Hydrochloride bulk offered by Sigma-Aldrich Corporation

    Find Sodium Benzoate bulk offered by Sigma-Aldrich Corporation

    Find Sotorasib bulk offered by Sigma-Aldrich Corporation

    Find Tripalmitin bulk offered by Sigma-Aldrich Corporation

    Find Urea C13 bulk offered by Sigma-Aldrich Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search